Cargando…

What Are the Incentives for Medicare Prescription Drug Plans to Consider Long-Term Outcomes and Cost?

BACKGROUND: Medicare Prescription Drug Plans (PDPs) do not have incentives to consider long-term outcomes and costs associated with both medical and pharmacy benefits (LTOCMP) when making formulary decisions. OBJECTIVE: To identify existing quality measures, payment models, and public reporting tool...

Descripción completa

Detalles Bibliográficos
Autores principales: Hung, Anna, Perfetto, Eleanor M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398251/
https://www.ncbi.nlm.nih.gov/pubmed/27348277
http://dx.doi.org/10.18553/jmcp.2016.22.7.773
_version_ 1785084026087800832
author Hung, Anna
Perfetto, Eleanor M.
author_facet Hung, Anna
Perfetto, Eleanor M.
author_sort Hung, Anna
collection PubMed
description BACKGROUND: Medicare Prescription Drug Plans (PDPs) do not have incentives to consider long-term outcomes and costs associated with both medical and pharmacy benefits (LTOCMP) when making formulary decisions. OBJECTIVE: To identify existing quality measures, payment models, and public reporting tools for PDPs that are related to formulary decision making and that could be used as potential incentives for PDPs to consider LTOCMP. METHODS: PubMed, Google, and quality measure databases, as well as Center for Medicare and Medicaid Innovation and Centers for Medicare & Medicaid Services (CMS) websites, were searched for appropriate quality measures, payment models, and public reporting tools. RESULTS: Few quality measures and other mechanisms exist that are related to formulary decision making and have the potential to be incentives for PDPs to consider LTOCMP. Only 3 such tools were identified: (1) Medicare Part D star ratings quality measures in use by CMS, (2) the Medicare Plan Finder website, and (3) URAC PBM Accreditation standards and measures. Furthermore, the majority of the quality initiatives identified were only indirectly related to motivating PDPs to consider LTOCMP. CONCLUSIONS: Efforts are needed to develop mechanisms to align PDP incentives with LTOCMP.
format Online
Article
Text
id pubmed-10398251
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-103982512023-08-04 What Are the Incentives for Medicare Prescription Drug Plans to Consider Long-Term Outcomes and Cost? Hung, Anna Perfetto, Eleanor M. J Manag Care Spec Pharm Subject Review BACKGROUND: Medicare Prescription Drug Plans (PDPs) do not have incentives to consider long-term outcomes and costs associated with both medical and pharmacy benefits (LTOCMP) when making formulary decisions. OBJECTIVE: To identify existing quality measures, payment models, and public reporting tools for PDPs that are related to formulary decision making and that could be used as potential incentives for PDPs to consider LTOCMP. METHODS: PubMed, Google, and quality measure databases, as well as Center for Medicare and Medicaid Innovation and Centers for Medicare & Medicaid Services (CMS) websites, were searched for appropriate quality measures, payment models, and public reporting tools. RESULTS: Few quality measures and other mechanisms exist that are related to formulary decision making and have the potential to be incentives for PDPs to consider LTOCMP. Only 3 such tools were identified: (1) Medicare Part D star ratings quality measures in use by CMS, (2) the Medicare Plan Finder website, and (3) URAC PBM Accreditation standards and measures. Furthermore, the majority of the quality initiatives identified were only indirectly related to motivating PDPs to consider LTOCMP. CONCLUSIONS: Efforts are needed to develop mechanisms to align PDP incentives with LTOCMP. Academy of Managed Care Pharmacy 2016-07 /pmc/articles/PMC10398251/ /pubmed/27348277 http://dx.doi.org/10.18553/jmcp.2016.22.7.773 Text en © 2016, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Subject Review
Hung, Anna
Perfetto, Eleanor M.
What Are the Incentives for Medicare Prescription Drug Plans to Consider Long-Term Outcomes and Cost?
title What Are the Incentives for Medicare Prescription Drug Plans to Consider Long-Term Outcomes and Cost?
title_full What Are the Incentives for Medicare Prescription Drug Plans to Consider Long-Term Outcomes and Cost?
title_fullStr What Are the Incentives for Medicare Prescription Drug Plans to Consider Long-Term Outcomes and Cost?
title_full_unstemmed What Are the Incentives for Medicare Prescription Drug Plans to Consider Long-Term Outcomes and Cost?
title_short What Are the Incentives for Medicare Prescription Drug Plans to Consider Long-Term Outcomes and Cost?
title_sort what are the incentives for medicare prescription drug plans to consider long-term outcomes and cost?
topic Subject Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398251/
https://www.ncbi.nlm.nih.gov/pubmed/27348277
http://dx.doi.org/10.18553/jmcp.2016.22.7.773
work_keys_str_mv AT hunganna whataretheincentivesformedicareprescriptiondrugplanstoconsiderlongtermoutcomesandcost
AT perfettoeleanorm whataretheincentivesformedicareprescriptiondrugplanstoconsiderlongtermoutcomesandcost